Women’s health franchise revenue trends
In 1H17, Teva Pharmaceutical Industries’ (TEVA) women’s health business reported revenues of ~$239 million, or ~5% higher YoY (year-over-year). In 2Q17, the business generated revenues of ~$115 million, or ~2% lower YoY and 7% higher QoQ (quarter-over-quarter).
TEVA’s women’s health products include ParaGard and Plan B One-Step. Plan B One-Step is a tablet containing levonorgestrel used as a birth control pill, while ParaGard is an intrauterine copper contraceptive.
Some important product launches in 2017
In July 2017, Teva launched the generic version of Novo Nordisk’s Vagifem in the US. Vagifem is an estradiol vaginal insert used for the treatment of atrophic vaginitis associated with menopause.
In May 2017, Teva launched generic versions of Valeant’s Glumetza 500 mg and 1,000 mg in the US. The Glumetza Metformin hydrochloride extended-release tablet is indicated, along with diet and exercise, for the management of high blood sugar levels in adult individuals with type-2 diabetes mellitus. The drug is not prescribed for individuals with type-1 diabetes or patients with diabetic ketoacidosis.
In March 2017, Teva launched generic versions of Pfizer’s Pristiq in the US. Pristiq (desvenlafaxine) is commercialized as an extended-release 25 mg, 50 mg, and 100 mg tablets. The drug is a serotonin and norepinephrine reuptake inhibitor used for the treatment of individuals with severe depression.
Teva’s peers in the women’s health market include Merck (MRK), Allergan (AGN), Eli Lilly (LLY), and Pfizer. Notably, the Vanguard International Dividend Appreciation ETF (VIGI) invests ~0.40% of its total portfolio in TEVA.